Abstract | BACKGROUND: METHODS: RESULTS: A total of 552 patients were identified; 58.7% were female, and the median age was 49 (interquartile range 40-57) years. In total, 291 (52.7%) patients were blocked with phenoxybenzamine, 114 (20.7%) with selective alpha blockers, 42 (7.6%) with only calcium channel blockers and/or beta blockers, and 76 (13.8%) with none. The proportion of patients blocked with phenoxybenzamine decreased from 71.0% in 2008 to 21.2% in 2019. The proportion of patients blocked with selective alpha blockers increased from 6.5% in 2008 to 42.4% and in 2019. The median cost of phenoxybenzamine increased from $722 (interquartile range $441-$1,514) in 2008 to $9,616 (interquartile range $5,049-$16,373) in 2019 (P < .001). Length of stay (2 [interquartile range 1-4] days vs 2 [interquartile range 0-3] days) and total perioperative costs ($24,250 [interquartile range $17,462-$33,849] vs $22,098 [interquartile range $16,341-$29,178] between phenoxybenzamine and selective alpha blocker groups were similar. CONCLUSION:
|
Authors | Eric J Kuo, Ling Chen, Jason D Wright, Catherine M McManus, James A Lee, Jennifer H Kuo |
Journal | Surgery
(Surgery)
Vol. 173
Issue 1
Pg. 19-25
(Jan 2023)
ISSN: 1532-7361 [Electronic] United States |
PMID | 36167697
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Elsevier Inc. All rights reserved. |
Chemical References |
- Phenoxybenzamine
- Calcium Channel Blockers
- Adrenergic alpha-Antagonists
|
Topics |
- Humans
- Female
- Adult
- Middle Aged
- Male
- Phenoxybenzamine
(therapeutic use)
- Retrospective Studies
- Calcium Channel Blockers
(therapeutic use)
- Pheochromocytoma
(surgery)
- Adrenal Gland Neoplasms
(surgery, drug therapy)
- Adrenalectomy
- Adrenergic alpha-Antagonists
(therapeutic use)
|